NCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
Clinical Trials
46 trialsNCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT01024920 2021-07-19
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Boehringer Ingelheim
Phase 2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01984242 2019-12-23
IMmotion150
Hoffmann-La Roche
Phase 2 Completed
NCT00709995 2019-09-30
A Study for Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01391130 2019-07-23
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Terminated
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT01506336 2018-12-11
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
AB Science
Phase 2 Completed
NCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT00864721 2018-10-16
Sunitinib Non Small Cell Lung Cancer Patients Over 70
US Oncology Research
Phase 2 Completed
NCT01829841 2018-05-03
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT00617253 2017-03-01
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Novo Nordisk A/S
Phase 2 Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed
NCT00982657 2015-11-20
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT00226811 2015-03-30
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
Pfizer
Phase 2 Completed
NCT01121562 2014-06-30
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 2 Completed
NCT00678119 2013-07-15
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Argos Therapeutics
Phase 2 Completed
NCT00662025 2013-05-27
Study Of Sunitinib With Capecitabine In Breast Cancer
Pfizer
Phase 2 Completed
NCT00265317 2013-02-06
SUN1058
Pfizer
Phase 2 Completed
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00338884 2012-08-31
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Pfizer
Phase 2 Completed
NCT00246571 2012-07-12
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Pfizer
Phase 2 Completed
NCT00668863 2011-10-17
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Pfizer
Phase 2 Completed
NCT00444314 2011-08-04
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
CASI Pharmaceuticals, Inc.
Phase 2 Completed
NCT00471276 2011-07-25
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT00243503 2011-07-22
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
Pfizer
Phase 2 Completed
NCT00372775 2011-02-24
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Pfizer
Phase 2 Completed
NCT00077974 2010-10-13
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Pfizer
Phase 2 Completed
NCT00113516 2010-05-18
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00254540 2010-02-23
Study of SU011248 in Patients With Advanced Kidney Cancer
Pfizer
Phase 2 Completed
NCT00247676 2010-02-18
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Pfizer
Phase 2 Completed
NCT00089648 2010-01-12
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Completed
NCT00434356 2009-12-03
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Genentech, Inc.
Phase 2 Terminated
NCT00137423 2009-09-30
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00137449 2009-09-15
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT00434226 2009-08-21
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Genentech, Inc.
Phase 2 Terminated
NCT00491738 2009-04-10
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Genentech, Inc.
Phase 2 Terminated
NCT00078000 2008-11-26
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Pfizer
Phase 2 Completed
NCT00092001 2008-10-16
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00056693 2008-07-21
Treatment With SU11248 in Patients With Neuroendocrine Tumors
Pfizer
Phase 2 Completed
NCT00077987 2007-01-11
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Pfizer
Phase 2 Completed